Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06563323 · ClinicalTrials.gov registry record · Phase 2
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
A Phase 2 study of Wound Heal and Skin Diseases, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT06563323 is a Phase 2 study of Wound Heal and Skin Diseases that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 17 participants, below the 119-participant average among 23 other Wound Heal trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06563323, a Phase 2 study of Wound Heal and Skin Diseases, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
Conditions Studied
Interventions
- DRUG Guselkumab
Study Locations (2)
Ohio
- Ohio State Dermatology - Columbus
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2027-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06563323
The ClinicalTrials.gov registry entry for NCT06563323 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 23 other Wound Heal trials with a reported enrollment target (86% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Wound Heal appearing as the primary indexed condition, and to 1 intervention - of which Guselkumab is the first listed.
NCT06563323 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Oregon.
Frequently Asked Questions
What is clinical trial NCT06563323 about?
NCT06563323 is a clinical study titled "Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)". A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
What is the current status of trial NCT06563323?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2025-02-01. Estimated completion is 2027-08-13.
What conditions does trial NCT06563323 study?
This clinical trial studies the following conditions: Wound Heal, Skin Diseases, Skin Ulcer, Pyoderma Gangrenosum, Pyoderma.
What interventions are being tested in trial NCT06563323?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT06563323?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06563323 being conducted?
This trial has 2 study locations across Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wound Heal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
4-aminopyridine for Skin Wound Healing
RECRUITING · Phase 2
-
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds
COMPLETED · Phase 2
-
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
COMPLETED · Phase 2
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
Dermabrasion in Mohs: Split-Scar Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.